Kerris Capital, a private investment manager that focuses on unique event-driven situations and long-term value investments recently published a negative report. The article describes the short position of the firm concerning Proteostasis Therapeutics. The corporation in question is a biopharmaceutical establishment that deals with the development phase of different drugs. Their principal focus is a drug entrant referred to as PTI-428. This drug was initially designed for the treatment of cystic fibrosis. When the FDA gave Breakthrough Therapy and the Orphan Drug designations, the stock prices of Proteostasis increase at a 100% rate.
According to Sahm Adrangi and Kerrisdale’s system analysis, the likelihood is that PTI-428 is not effective. The company detected some low-quality facts and disturbing omissions in the product details made available to the public by Proteostasis. Owing to the short position Kerrisdale Capital and Sahm Adrangi have regarding Proteostasis Therapeutics once the prices of the shares decrease the company might benefit.
Sahm Adrangi established Kerrisdale Capital Management and currently serves as the Chief Investment Officer of the establishment. Since its inception, Kerrisdale has always participated in all matters regarding the development of the company. Sahm began Kerrisdale Capital with less than a million dollars, but by July 2017, the firm was handling over 150 million dollars.
Adrangi is popularly known due to his short selling as well as publishing research endeavors. His views concerning stocks include under followed longs and overhyped shorts. Nevertheless, these views are not yet well-known in the market. The research carried out by Kerrisdale corrects any misconceptions associated with the critical business opportunities of various establishments. The company then shares the research on Kerrisdale’s website, Twitter, and other investment related websites as well.
Over the years, Mr. Sahm Adrangi has built a name for himself by shorting and also exposing several fraudulent Chinese businesses including China Marine Food Group, Lihua International, and China-Biotics, among others. His research has led to prosecution measures against China Education Alliance and ChinaCast Education Corporation from the Exchange and Securities Commission.
Additionally, Sahm Adrangi typically specializes in particular industries mostly because of his experience and competence. One of these industries includes the biotechnology field. In the recent past, Kerrisdale has published lots of information on development-stage corporations including Unilife, Pulse Biosciences, Bavarian Nordic and Sage Therapeutics. The other fields include telecommunications and mining prospects.